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Injury to the adult mammalian spinal cord leads to permanent loss of controlled neurological function. Endogenous repair 
mechanisms fail to reestablish functional synoptic connections. Moreover, neurological outcome usually gets worse in time, due to 
neurodestructive processes inherent to the adult spinal cord. Surgical repair strategies need to focus on replacing damaged/ lost 
nervous tissue, promoting axonal regeneration and reestablishing functional synaptic contacts. This review will discuss the current 
understanding of the potential beneficial role of Schwann cells, neurotrophic factors, biodegradable polymers or combinations 
thereof in spinal cord injury. Replacement, of injured spinal tissue with a Schwann cell graft promotes axonal regeneration and 
myelination. Neurotrophic factors initiate and/or enhance events that are crucial for functional recovery, such as cell survival and 
axonal regeneration. Biodegradable polymers can be used as a scaffold for cell implantation and/or as a drug delivery vehicle. The 
complex nature of spinal cord injury demands a combinatorial restorative approach. For the future, the challenge will be to combine 
individual growth-promoting properties such that neurological recovery in spinal cord injured humans can be achieved. Biomed Rev 
1999; 10: 75-88. 
 
INTRODUCTION 
Damage to the spinal cord initiates a cascade of neural and 
neuronal events, which results in permanent damage and loss of 
neurological function. Within minutes to hours after an injury, 
neutrophils, polymorphonucleargranulocytes, andmacrophages 
invade the damaged area (9) and local resident microglial cells 
become activated (70). These inflammatory events, together 
with ischemia (39,125) and Ca
2+
 influx into cells (39), are thought to 
contribute to secondary injury, which causes progressive loss of 
spinal tissue (13,50,141). In human spinal cordinjury, the loss of 
gray matter is often localized to one or a few segments, but its 
extension across the diameter of the cord leads to significant 
loss of white matter (131). This results in the 
interruption of descending and ascending fiber tracts and 
further functional impairment (25). 
Initially following injury some neurons switch into a restorative 
mode, as evidenced by a transient upregulation of regeneration-
associated genes (127,128). Nevertheless, spontaneous axonal 
growth does not occur mainly due to the presence of reactive 
astrocytes (44) and neurite growth-inhibitory molecules (37,44, 
100) at the site of injury. This failed regeneration leads to axonal 
dieback, neuronal atrophy, and possibly death (74). 
Acute treatment strategies for petients with spinal cord injury 
focus on preventing injury-induced spinal tissue loss. Currently, in 
the United States, a high dose of the corticosteroid and 
antioxidantmethylprednisoloneis administered within 8 hours 
after injury (17,18). This reportedly reduces spinal tissue loss, 
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but only modestly improves motor and sensory function (16,18). 
Due to the lack of efficacy of current acute treatments, permanent 
neurological damage is inevitable and surgical strategies have to 
be developed aimed at replacing damaged spinal tissue and 
promoting axonal regeneration. 
SPINAL CORD IMPLANTATION STRATEGIES 
Central nervous system (CNS) neurons are intrinsically able to 
regenerate their axon following damage. However, injury-
induced tissue loss, gliosis and expression of axonal growth-
inhibitory factors create an environment hostile to axonal 
growth within the adult spinal cord. Implantation of an axonal 
growth-permissive environment has long been recognized as 
an effective approach to replace damaged spinal tissue and 
promote axonal regeneration. Implants that have shown to 
promote axonal regeneration in nonprimate mammals include 
fetal tissue (4,20,109,110,126), peripheral nerve grafts (2,34,35,93-
95,112), cultured and genetically modified fibroblasts (75, 
85,123,129,134), olfactory ensheathing cells (73,104-106) and 
Schwann cells (SC) (24,26,32,55,96,137-139). In this review, the 
use of SC in spinal cord repair strategies will be dealt with 
especially, but other implants will also be mentioned. 
One implant may be preferred over the others depending on 
the type and size of the injury. A contusion cavity may be filled 
with a suspension of fetal tissue (49,60,109), fibroblasts (85), 
olfactory ensheathing glia, or SC (82,99,136), which can be 
achieved without much further damage to spared spinal tissue. A 
partial or complete transection of the spinal cord may require 
solid implants of fetal tissue, peripheral nerve or preformed 
grafts of fibroblasts or SCs that bridge the lesion gap. Although 
some modestrecovery following implantation of only an axonal 
growth-promoting graft has been reported, it is generally 
accepted that a combination of interventions is necessary to 
achieve substantial recovery of neurological function. 
SCHWANN CELL IMPLANTATION IN THE INJURED 
SPINAL CORD 
Early this century Santiago Ramon y Cajal (107) implanted 
peripheral nerve grafts into the spinal cord and observed central 
axon growth. Although this growth appeared to be abortive, 
Cajal and others recognized the powerful growth-promoting 
properties of the major cellular component of peripheral nerves, 
the SC. Richard Bunge was one of the first to acknowledge the 
possibility to isolate and culture these cells from a patient's 
nerve for autologous implantation in injured spinal cord. 
Presently, large numbers of SC can be generated from adult rat 
peripheral nerve (90) and from human nerve (29,71,114). SC 
secrete neurotrophic factors, express cell adhesion molecules, 
and generate several extracellular matrix molecules, which all 
can positively influence axonal growth. The efficacy of SC in 
promoting axonal regeneration in the injured spinal cord has 
been studied extensively (22-24,26,54). Adult rat sciatic nerve 
SC, mixed in Matrigel, a basal lamina matrix, and contained in a 
semipermeablepolyacrylonitrile/polyvinylchoride(PAN/PVC) 
polymer tube (Fig. 1 a), implanted in the completely transected 
adult rat thoracic spinal cord promote axonal growth (137,139). 
Within a few weeks, the spinal cord stumps are bridged by a 
tissue cable (Fig. lb,c) that contains SC (Fig. le,f), ensheathed 
unmyelinated andmyelinatedaxons (Fig. Id,e,g), blood vessels 
(Fig.Id), fibroblasts, meningeal cells and usually a few 
macrophages (32,96,137-139). An estimated 25% of the total 
number of fibers is myelinated by SC. Retrograde tracing 
experiments revealed that the maj ority of the axons derive from 
propriospinal neurons located as far rostrally as the third 
cervical spinal cord level and as far caudally as the fourth sacral 
level (139). The responding axons grew across the graft but did 
not enter the opposite cord stump. Also, supraspinal fibers 
were not found in these grafts. Important for future human 
application is that implantation of isolated human SC in the nude 
(T-cell deficient) rat elicits an axonal growth response (55). 
Following implantation of aSC graft, usually loss of nervous 
tissue at the graft-host cord interfaces occurs and this may 
restrict an optimal regenerative response. A combination of a 
SC implant and methylprednisolone treatment shortly after the 
injury/implantation limits the loss of tissue at the interface, 
enhances the number of axons, and promotes supraspinal 
growth into the SC graft (32). The observed preservation of 
nervous tissue and enhanced axonal growth may be related to 
the methylprednisolone-induced decrease in the number of 
microglia/macrophages near the injury site (98). 
As alluded to above, other grafts such as fetal tissue, peripheral 
nerve, genetically modified fibroblasts or olfactory ensheathing 
glia have been used successfully in injured spinal cord. The 
main advantage of SC over these grafts is that SC also myelinate at 
least a portion of the regenerating fibers. Following injury, 
oligodendrocytes near the lesion site die (1,43), which results in 
demyelination, even of initially undamaged axons. SCs could 
replace these oligodendrocytes and remyelinate new axon 
sprouts as well as demyelinated intact axons. Implantation of a 
SC graft alone in the injured adult rat spinal cord usually does 
not result in growth of axons from the graft into the spinal tissue 
beyond (24,139). Clearly, additional interventions need to be 
combined with SC implantation to achieve reentry of 
regenerating fibers into the spinal cord (see below). Nevertheless, 
the studies mentioned above have established the SC as an 
important candidate for future surgical repair strategies aimed at 
functional recovery in humans with spinal cord injury. 
MEUROTROPHIC FACTORS IN THE INJURED SPINAL CORD 
During CNS development neurons depend for their survival and 
function on neurotrophic factors, which are produced by neurons 
and glial cells in their vicinity or innervation territory (72). The 





Oudega and Gautier 76 
Biomed Rev 10, 1999 
Neurotrophic factors in spinal cord repair 
  
 
Figure 1. Schwann cell implantation in the completely transected adult rat thoracic spinal cord. Schwann cells mixed with 
Matrigel and seeded (a) into a nondegradable, semipermeable polyacrylonitrile/polyvinylchoride tube (P) form a compact 
Schwann cell cable (SCC). Four weeks after implantation (b), the SCC has fused well with the spinal cord (SC) bridging the 
opposite cord stumps. At this time, the cable is surrounded by a few layers offibroblasts (c) and contains fascicles ofmyelinated 
axons (d) as well as blood vessels (asterisks in d). Panal (e) demonstrates myelinated (MA) and unmyelinated axons present in 
the SCC at 4 weeks after implantation. Immunocytochemistry for SI 00 and neurofilaments revealed that (f) the Schwann cells 
and (g) ingrowing axons are longitudinally arranged within the cable. 
  
derived neurotrophic factor (BDNF), neurotrophin-3, -4/5 and-6 
(NT-3, NT-4, NT-6) (7,15), which are all homodimers of two 
approximately 120 amino acid proteins (~ 13 kD; 62). Neurotrophic 
factors are structurally and functionally homologous and 50-
60% identical in amino acid sequence. They bind to and activate 
high-affinity transmembrane tyrosine kinase (Trk) receptors 
that interact with several identified intracellular signaling 
pathways (7,15,31,58,122). NGF specifically activates TrkA, 
BDNF and NT-4 activates TrkB and NT-3 activates TrkC, and in 
some cell types TrkB. All the neurotrophic factors can bind to 
the low-affinity p75 neurotrophin receptor (p75NTR), amember of the 
tumor necrosis factor receptor superfamily( 15,31,58), which is 
involved in increasing or decreasing Trk phosphorylation in the 
presence or absence, respectively, of the ligand. Through TrkA-
independent activation of the ceramide pathway (30,42), p75NTR 
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Following injury to the adult rat CNS, the synthesis of several 
neurotrophic factors is up regulated (38,89). This response may 
be mediated by cytokines, such as interleukin-1 (IL-1), which is 
released by microgliaand immune cells (38). The injury-induced 
increase in the level of neurotrophic factors is not sufficient or 
does not occur at the right time to effectively prevent degeneration 
and promote regeneration in the CNS. 
Neurotrophic factor-promoted axonal growth into an 
intraspinal graft 
As described above only a relatively small percentage of the 
available injured axons usually regenerate into spinal cord 
grafts. It has been demonstrated repeatedly that increasing the 
levels of neurotrophic factors in the graft environment enhances 
the axonal growth response. A 2-week infusion of BDNF and 
NT-3 directly into a SC graft placed in the completely transected rat 
spinal cord increases the number of responding fibers twofold 
and recruits fibers from neurons in 10 different brainstem nuclei 
(138). Most of the responding supraspinal fibers are 
vestibulospinal fibers. It is not clear whether both neurotrophins 
are necessary to elicit this growth response. SC genetically 
modified to produce and release NGF and placed in a hemisection 
were shown to promote axonal growth of neurons located in the 
spinal cord and dorsal root ganglia (DRG) (130,134). Also, 
implantation of a 5mm long trail of BDNF-secreting SC into the 
distal stump of the transected adult rat spinal cord promotes 
regeneration of axons from neurons of brainstem nuclei across 
the transection site into the implant (88). The growth response 
appears specific for the secreted neurotrophic factor since many of 
the responding axons were found to derive from neurons 
known to express TrkB. 
It is clear that an increased level of neurotrophic factors 
enhances the axonal growth response into intraspinal SC 
implants. It is important to note that not every combination of 
growth factors will effectively promoting axonal regeneration. 
For instance, the combination of a SC graft with insulin-like 
growth factor and platelet-derived growth factor did not result in 
enhanced axonal growth in the injured adult rat spinal cord (96). 
In this particular study, relatively more myelinated axons (with 
thicker myelin sheaths) but fewer unmyelinated axons were 
present in the graft and more nervous tissue loss was 
observed in the graft-host cord interface. These findings and 
other (32) suggest that the magnitude of the regenerative 
response is related to preservation of the interface. 
Neurotrophic factors have also been demonstrated to 
effectively increase the growth response in combination with 
other intraspinal grafts than SC grafts. An enhanced regenerative 
response was found in grafts containing fibroblasts genetically 
modified toproduceNGF(12,67,129),BDNF(67,75),orNT-3(53). 
Fibroblasts secreting BDNF or NT-3 were found to induce 
oligodendrocyte proliferation and myelination of regenerating 
axons when placed in a contused adult rat spinal cord (85). 
Neurotrophic factor-promoted axonal growth from a graft 
into spinal tissue 
To effectively repair spinal cord injury, axons need to regenerate 
from the implant into the spinal cord and establish functional 
synapses with neurons that are involved in the lost neurological 
function. Spontaneous growth of fibers from a graft into the 
spinal cord has been shown sporadically and only over short 
distances. More substantial reentry of fibers into the spinal cord 
can be achieved by increasing the level of neurotrophic factors a 
distance away from the graft (Fig. 2; 94,95). The rationale for 
these experiments is based on the in vitro observation that NGF 
cannot induce axonal outgrowth into an environment with lower 
NGF levels (28). In adult rats with a 1-week old conditioning 
lesion of the sciatic nerve and apredegenerated peripheral nerve 
bridge (Fig. 2a,c) in the thoracic dorsal funiculus (93), a 2-week 
infusion of NGF into the spinal cord 3-5 mm rostral from the 
rostral end of the nerve graft (Fig. 2b,d) promotes outgrowth of 
approximately 50% of the sensory fibers into the dorsal funiculus 
white matter (Fig. 2c,d,e; 94). The number of axons decreased 
further away from the graft and 10-20% reached the infusion site 
(Fig. 2e) but not farther, probably because of the chemoattractant 
effects of NGF (56,57,72). A largely similar response was seen 
after infusion of BDNF, NT-3 or a combination of all three 
neurotrophic factors (95). Possibly, infusion of neurotrophins 
over a time period longer than 2 weeks would further enhance 
axonal growth into the spinal cord. Recently, neurotrophic 
factor infusion was shown to promote growth of descending 
fibers from a SC implant into the distal spinal cord (140). In this 
study, the factors were infused over a 4-week period and the 
reentering axons could be seen beyond the site of infusion. 
Normally, in the adult rat, sensory projections of dorsal root 
ganglia (DRG) neurons regenerate very well in aperipheral nerve or 
dorsal root environment after a crush injury (102) but do not 
cross the dorsal root-spinal cord interface, even after a 
conditioning lesion of the peripheral nerve (94). Infusion of NGF in 
the lumbar cord 3-4 mm away from the entrance zone of the 
crushed L4 dorsal root (L3,5, and 6 roots were resected) results in 
growth of approximately 20% of the sensory axons from the root 
into the spinal cord towards the infusion site (94). Clearly, 
limited growth of axons from a graft into spinal tissue results at 
least partially from insufficient levels of neurotrophic factors in 
the spinal cord and/or from their chemoattractant properti es that 
would limit growth away from the neurotrophic factor source, 
i.e., the graft environment. However, in the studies alluded to 
above, the improved regeneration into the spinal cord involves 
only a small number of axons and the elongation of the long 
projecting axons is limited to relatively short distances when 
considering the total length of the spinal cord. To accomplish 
topographical and functionally appropriate connections, which 
usually requires growth over longer distances, more than merely 
implantation of a graft and increasing the level of neurotrophic 
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Figure 2. Neurotrophins promote axonal growth from a graft into the spinal cord. A peripheral nerve graft (G) implanted into the 
spinal cord dorsal columns (DC) fuses well with spinal cord tissue (a). A few small cavities are observed near the graft-host 
cord interface (stars in a) in the DC or dorsal horn (DH). Similarly, placement of a metal infusion canulla into the dorsal spinal 
cord (b) results in relatively minor damage (star in b) of the spinal tissue around the infusion site (IS). The asterisk (b) is placed in 
an area that was damaged during histological preparation of the tissue. A 2-week infusion of mouse NGF (m NGF) or recombinant 
human NGF (rh NGF) 3-4 mm way from the rostral nerve graft-host cord interface (c) promotes outgrowth of sensory fibers from 
the graft into the spinal cord dorsal columns (DC). These fibers grow as far as the infusion site (IS, d) but not further (e). In the 
graph (e), the 0.0 level represents the rostral end of the peripheral nerve graft The arrow indicates the 3mm level where the 
infusion canulla was placed. 
  
Other strategies to improve growth into the spinal cord have 
also been successful. Combining a SC graft with methylpred-
nisolone treatment shortly after injury/implantation resulted in 
reentry of axons into the distal cord, albeit over a relatively short 
distance (24). Substantial growth of fibers into the spinal cord 
was also achieved by combining a SC graft with olfactory 
ensheathing glial cells implanted in the graft-host cord interfaces 
(105). Serotonergic fiber growth into the distal cord was observed 
after stabilizing the transected spinal cord using compressive 
wiring of the dorsal vertebral processes (33). Also, this stabilizing 
technique combined with implantation of 18 intercostal nerve 
grafts resulted in growth of several long descending fiber tracts, 
including the corticospinal tract, through the nerve grafts into 
the distal spinal tissue (34). The nerve grafts routed spinal cord 
fiber tracts from nonpermissive white matter to permissive gray 
matter and were embedded in fibrin glue containing acidic 
fibroblast growth factor. These findings are exciting as well as 
surprising and need to be confirmed in the future. In addition, 
elucidation of the mechanisms responsible for these findings 
would make it possible to effectively promote other fiber tracts 
involved in locomotion. 
Recently, implantation of olfactory ensheathing glia in 
between spinal cord stumps following a complete transection 
(106) or into an electrolytic lesion in the dorsal funiculus (73) was 
also shown to promote axonal growth across the injury site and 
into 'spinal tissue beyond. In these studies the olfactory 
ensheathing cells were accompanying the reentering axons, 
suggesting that as long as regenerating fibers are not or 
minimally exposed to interface tissue they will grow across this 
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of the graft-host cord interfaces are of crucial importance to 
axonal reentry into the spinal cord. Strategies such as the 
chemical neutralization or destruction of these growth inhibitors 
(19,117-119,142) may prove to be successful forreentry of fibers 
and, consequently enhancing the chances for functional 
recovery. 
MECHANISMS OF THE NEUROTROPHIC FACTOR-
ENHANCED AXONAL REGENERATION 
Neurotrophic factor-promoted axonal growth into an intraspinal 
graft may be due to the chemoattractant effects of the factors, 
which would result in growth towards the higher concentrations, 
i.e., the implant environment. Alternatively, the presence of 
neurotrophic factors in the graft and especially near the graft-
host interface may allow for the internalization of the factors by 
transected axons. Subsequent retrograde transport to their cell 
body (41,92) can then activate second message systems involved in 
regeneration. For example, it has been shown that BDNF 
infused near the red nucleus induces the expression of 
regeneration-associated genes in axotomized rubrospinal 
neurons (128). The switch from synthesizing function-related to 
regeneration-related proteins elicits axonal growth (14,51). At 
this time it is unclear whether neurotrophic factors can also 
activate intracellular signaling at the distal end of growing axons 
(63). It is important to expanding our knowledge about where 
neurotrophic factors act since this will govern where treatments 
would be best applied. 
An alternative mechanism by which high levels of neurotrophic 
factors in the graft environment can enhance axonal regeneration is 
by preventing or limiting injury-induced axonal and spinal 
degeneration at the graft-host cord interfaces. This would 
increase the number of available injured axons to grow into the 
graft. Normally, following spinal cord injury, axons disintegrate 
and form swellings or terminal clubs on the proximal axonal 
stumps (48,65). Release of hydrolytic enzymes from these clubs is 
thought to significantly contribute to the secondary spinal cord 
damage. Neurotrophic factors can prevent the formation of 
terminal clubs in the transected ascending sensory tracts (116). 
Also, neurotrophic factors can prevent axonal dieback or 
degeneration (133) and neuronal atrophy (21). This may be 
relevant to humans with a contusion injury, where immediately 
after the damage a large number of axons may still be intact. Early 
administration of neurotrophic factors may prevent degeneration of 
the undamaged axons and thus maintain functional axonal 
connections, i.e., limit neurological dysfunction. 
The mechanisms of neurotrophic factor-promoted axonal 
growth from a graft into the spinal cord are unclear. Possibly, the 
chemoattractant effects of neurotrophic factors may elicit growth of 
fibers from the graft into the otherwise growth-inhibitory adult 
spinal cord tissue. This would imply that neurotrophic factors 







to induce regeneration into the appropriate target tissues. 
However, an implant of BDNF-secreting fibroblasts in the    
injured rubrospinal tract promotes axonal growth into the spinal   
cord distal to the implant, i.e., away from the highest concentration    
the neurotrophic factor (75). An other mechanism could be    
neurotrophic factors modify local cells (astrocytes, 
oligodendrocytes, microglia and white blood cells) such that they 
release regeneration-promoting substances, which would make the 
spinal tissue more permissive for axonal growth. Alternatively, 
neurotrophic factors may affect the expression of neurite growth-
inhibitory molecules at the graft-host cord interfaces. 
The likely role of neurotrophins in future repair strategies for 
spinal cord injury brings about two other important issues; 
where and how to deliver the neurotrophic factors to achieve an 
optimal growth response. Different methods of delivery are 
currently being explored. Important considerations for treatments 
are the location and extent of the injured region since, ideally, 
the treatment should only affect this region. Also, as with any 
pharmacological intervention, it would be important to be able 
to control the dose and the time-course of administration, 
including the termination of the neurotrophic factor treatment. 
Injections or infusions of neurotrophic factors directly into the 
injured spinal cord region would result in local effects and also 
permit regulation of the dose and timing of the treatment. Also, 
injections of viral vectors with genes for new and continuous 
synthesis of neurotrophic factors by spinal cord cells or of 
molecules that mimic the binding sites of neurotrophic factors to their 
receptors (62) could result in locally increased levels of 
neurotrophic factors. Increased levels of neurotrophic factors can 
also be achieved by implanting slow-release polymers j that contain 
neurotrophic factors (59). However, a disadvantage of these site-
specific delivery techniques is that it will most likely induce additional 
damage to the already injured spinal cord. 
An alternative delivery technique for neurotrophins for which the 
spinal cord is readily accessible is intrathecal administration. In most 
injury cases, neurotrophins may be able to enter the cord from the 
cerebrospinal fluid because for at least a short period of time the 
injury site has a reduced blood-brain barrier (BBB). At later time 
points, carrier molecules such as antibodies to    | transferrin 
receptor could be used to shuttle neurotrophic    \ factors across 
the intact/restored BBB (52,68). Another potential    j delivery 
approach is based on the fact that almost all neurotrophic    j factors are 
produced in the CNS. Thus, agents may be developed    ' that can 
upregulate the synthesis of these endogenous sources     : (115). 
However, these delivery techniques result in a systemic 
administration of neurotrophic factors and, as with all 
pharmacological agents, may result in side effects because 
many neurotrophic factors also play physiological roles in 
nonnervous tissues. Side effects were observed in the recent 
clinical trials with CNTFfor amyotrophic lateral sclerosis (3). 
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POLYMERS IN SPINAL CORD REPAIR 
Natural and synthetic polymers have been used extensively in 
spinal cord repair strategies as amatrix for cellular implants and/ or 
a scaffold for regenerating axons. Fibrin containing acidic 
fibroblast growth factor and combined with peripheral nerve 
grafts and stabilization of the lesion site was found to promote 
growth of long descending fiber tracts across and beyond the 
implanted area (34). Implants of solid (81) or fluid collagen (64) 
also promote axonal growth in the injured adult rat spinal cord. 
Other polymers that have been used in spinal cord repair 
strategies include carbon filaments (66), nitrocellulose 
membranes (61), polyacrylonitrile-poly vinylalcohol tubes (83), 
polyacrylonitrile-poly vinylchloride tubes (32,55,96,137,138), and 
polymethacrylate porous hydrogels (135). 
Polymer structures in spinal cord injury paradigms need to 
fulfill several requirements. The device should be (i) porous to 
allow migration of cells and/or ingrowth of axons as well as 
exchange of nutrients, (ii) supporting or even promoting axonal 
regeneration, (Hi) three-dimensional with preferably 
longitudinally oriented pores, (iv) biodegradable, and (v) 
biocom-palible, i.e., not induce an inflammatory or immune 
response above that normally seen in spinal cord injury. The 
incorporation of axonal growth-promoting factors within the 
polymer would enhance the axonal growth response. 
Moreover, with a biodegradable polymer the release of these, 
growth-promoting factors would be temporary for as long as the 
degradation takes place. 
Polymers that potentially fulfill all the requirements listed 
above are those derived from lactic and glycolic acids, the 
aliphatic poly(ohydroxyacids). The main advantage of this 
family of polymers is that their degradation and mechanical 
properties can be fully accustomed. These properties depend 
on the ratio of the L-lactic (L-LA), D-lactic (D-LA) and glycolic 
(GA) acid repeating units, their distribution along the 
macromolecular backbone and their molecular weight 
distribution (132). Poly (a-hydroxyacids) can be manufactured 
into porous structures with controlled porosity, pore size and 
orientation (78, 79). Moreover, following implantation, these 
polymers do not provoke immunologic reactions (86) and are 
completely resorbed (6). PLA/GA were used as temporary 
prostheses and scaffolds for cell implantation in a wide variety 
of structures and shapes (78,79). Besides in injured peripheral 
nerves in animals (40,108) and humans (77), poly(oc-hydroxyacids) 
have also been used for the repair of cartilage and liver (36), skin 
(11), and urothelial tissues (5). 
In the CNS, poly(oc-hydroxyacids) implants have been used 
mainly as controlled delivery systems for bioactive 
(macro)molecules (10,69,87). Rods and microspheres made of 
po!y(D,L-lactic acid) were implanted in the rat brain for the 
delivery of neurotrophic factors (69). They were found to 
provoke a typical astrocytic and inflammatory response in the 
brain (69,87). At present, a clinical trial is underway with 
microspheres loaded with 5-fluorouracil injected prior to 
radiotherapy of patients with glioblastoma (10). 
ALIPHATIC POLY(oc-HYDROXYACIDS) IN SPINAL CORD 
REPAIR STRATEGIES 
So far, aliphatic poly(oc-hydroxyacids) have sporadically been 
used in the injured spinal cord. In an attempt to design 
biodegradable scaffolds for the implantation of SC in the injured 
adult spinal cord, the biocampatibility of poly(oc-hydroxyacids) 
with SC and adult spinal tissue was investigated (47). In vitro, it 
was demonstrated that PLA/GA and its breakdown products had 
no adverse effect on the morphology, survival and 
proliferation of cultured rat SC (Fig. 3a-c). In fact, the SCs had 
formed extensions that were in close contact with the PLA/GA 
(Fig. 3c). In vivo, a2-mm long PLA/GA disc implanted in between 
the stumps of a transected adult rat thoracic spinal cord was 
shown to integrate well into spinal tissue at two weeks after 
implantation (47). At all time-points post-implantation, the 
astrocytic (Fig. 3d versus 3e) and inflammatory response (Fig. 3f 
versus 3g) near the lesion site was largely similar in both 
experimental and controls animals, from which a 2-mm long 
spinal segment was removed only. Neuro filament-positive fibers 
were found growing into the PLA/GA disc or the remains 
thereof. Moreover, GAP-43, a protein indicative of regenerating 
axons, was found in some of these fibers in the remains of the 
PLA/GA discs (47). The results suggest that poly(a-
hydroxyacids) and their breakdown products are not hostile to 
SC nor to regenerating axons. In another study, PLA needles 
with 100 |im wide longitudinal grooves and embedded in fibrin 
glue were implanted in a similar complete adult spinal cord 
transection model (80). Cell migration, angiogenesis and axonal 
growth was observed within this implant. The longitudinal 
orientation of the needles and their macropores appeared to 
benefit blood vessel and axonal growth (80). 
In most of the experiments alluded to above, in which SC were 
implanted into the injured spinal cord, the SC were enclosed in a 
nondegradable PAN/PVC tube. A tubular scaffold for cell 
implantation may improve axonal regeneration by limiting the 
formation of scar tissue and by allowing the accumulation of 
neurite growth-promoting factors (23). These properties are 
thought to be especially beneficial for axonal growth in the early 
phase of the regeneration response (45). However, in later 
stages of the growth response the presence of a tubular scaffold 
may actually restrict axonal growth or the maintenance of fibers 
that have grown into the implant due to constriction of the spinal 
cord, toxicity, or foreign body reaction, which may develop over 
the long term. The use of a biodegradable tubular scaffold for 
SC implantation into the injured spinal cord may circumvent 
these detrimental effects. Preliminary results have revealed that 
axons do grow into an implant of SC contained in a tubular PLA 
scaffold implanted into the completely transected adult rat 
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Figure 3. Schwann cells and spinal cord tissue are not affected by poly (a-hydroxyacids) or their breakdown products. In 
vitro 
Schwann cells proliferate at a similar rate without (a) or with (b) poly(a-hydroxy acids) p) present in the cuUuredtshThe 
Schwann cells even form extensions (c) that grow towards the polymer. In vivo, implantation of a 2 mm-long poly(a-
h^Zacid cylinder (P in panel e andg) does not result in an astrocytic (d versus e) or inflammatory (/versus g) response 
beyond ^a,leer after a transection and removal of 2 mm of spinal cord (SC) only (d andf). Panel d ande show horizontal 
cr^ostat sections stained with antibodies against glial fibrillary acidic protein, a marker for astrocytes Panel fond g show 
hor^'^ostat sections stainedwith antibodies against ED-1, a marker for microgliaSmacrophages. The arrow heads pomt at 
the rostral end of the transected spinal cord. 
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the tissue cable decreased due to damage by parts of the 
degrading scaffold. Possibly, the nonuniformly breakdown of 
these tubes may have resulted in the formation of large pieces of 
the scaffold that caused damage to the tissue cable inside. 
Future experiments need to focus on the development and use of 
biodegradable scaffolds that degrade uniformly. Also, the 
incorporation of growth promoting factors into these tubular SC 
scaffolds or the implantation of SC containing multichannel 
scaffolds with or without these factors may substantially improve 
the axonal regeneration response. 
CONCLUSION 
The consequences of a spinal cord injury are devastating and 
the complexity demands a multifactorial repair strategy. SC have 
been shown repeatedly to possess properties beneficial for 
spinal cord repair strategies. Neurotrophic factors have been 
shown to play a crucial role in enhancing the regenerative 
response and to achieve lengthy regeneration across and 
beyond an intraspinal implant. Neurotrophic factors are also 
likely to play a role in preventing degeneration of axons after 
spinal cord injury. A clinically relevant question is whether 
chronically injured neurons remain responsive to SC and/or 
neuro trophic factors. Neutralization of axonal growth inhibitors in 
injured spinal tissue can result in lengthy regeneration of a 
limited number of axons (27,118). Neurotrophic factors combined 
with such an approach may further enhance the regenerative 
response (117). Another promising area in spinal cord repair 
strategies, which need further in depth study, is the 
pharmacological prevention of additional loss of tissue and/or 
spared axonal connections. The development of such acute 
treatments may, in some but not all spinal cord injuries, simplify the 
complex task of promoting long-distance regeneration and 
functionally appropriate reinnervation. 
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